Oncocross

온코크로스 · 382150

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$48.1M (₩66.3B)

Overview

Oncocross uses artificial intelligence to analyze biological and chemical data in order to identify new uses for existing drugs, a process known as drug repurposing, and to support the discovery of new medicines.

Its services are aimed at pharmaceutical companies, research institutions, and others working in drug development. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$268.4K

▼ −65.4% YoY

Operating profit · FY2025

−US$6.4M

Loss widened

Net income · FY2025

−US$6.5M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$66.3K(₩91.5M)	US$777K(₩1.1B)	US$268.4K(₩370.5M)
Operating profit	−US$4.9M(−₩6.8B)	−US$5M(−₩7B)	−US$6.4M(−₩8.8B)
Net income	−US$3.1M(−₩4.2B)	−US$4.7M(−₩6.5B)	−US$6.5M(−₩8.9B)

Revenue

FY2023US$66.3K
FY2024US$777K
FY2025US$268.4K

Operating profit

FY2023−US$4.9M
FY2024−US$5M
FY2025−US$6.4M

Net income

FY2023−US$3.1M
FY2024−US$4.7M
FY2025−US$6.5M

Key ratios (FY2025)

ROE

-66.8%

Debt/Eq

116.5%

Op. margin

-2383.0%

Net margin

-2410.2%

Rev. YoY

▼ −65.4%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?